The insightful review by Bonilla-Santos et al. highlights that neuroinflammation alterations in Alzheimer’s disease (AD) constitute a priority therapeutic target, especially in the early stages of mild cognitive impairment, when biological and behavioral markers precede anatomical damage. In this context, identifying plant-derived compounds with anti-inflammatory and antioxidant activity, capable of modulating relevant cell signaling pathways, is pertinent for future pharmacological development. This letter aims to emphasize the potential of Buddleja globosa (Matico) as a source of phenolic compounds of neuroprotective interest in AD.
Publicación Oficial de la Sociedad Ecuatoriana de Neurología, de la Liga Ecuatoriana Contra la Epilepsia y de la Sociedad Iberoamericana de Enfermedad Cerebrovascular
